Pancreatic cancer: current standards, working towards a new therapeutic approach.

Abstract:

:Pancreatic cancer is the fourth leading cause of cancer deaths with a 5-year survival of 4-6%. Clinical challenges remain to be addressed, since few promising approaches to treat pancreatic cancer have been reported. Here we discuss the potential of a new biotherapeutic agent composed of a lysosomal protein (Saposin C, SapC) and an acidic phospholipid (dioleoylphosphatidylserine, DOPS) which can be assembled into stable nanovesicles (SapC-DOPS) for tackling pancreatic cancer. Phosphatidylserine (PS) is a lipid biomarker on membrane surface of pancreatic cancer cells and can be effectively targeted by SapC-DOPS nanovesicles for cancer-selective therapy. SapC-DOPS nanovesicles have shown excellent pre-clinical therapeutic and safety profiles. Safety profiles which suggests that this new approach is potentially a viable option for pancreatic cancer therapy that is worthy of further clinical development.

authors

Olowokure O,Qi X

doi

10.1586/14737140.2014.895937

subject

Has Abstract

pub_date

2014-05-01 00:00:00

pages

495-7

issue

5

eissn

1473-7140

issn

1744-8328

journal_volume

14

pub_type

社论
  • Satraplatin: an orally available platinum analog for the treatment of cancer.

    abstract::Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous i...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.7.973

    authors: Choy H

    更新日期:2006-07-01 00:00:00

  • Abdominal wall desmoid tumors associated with pregnancy: current concepts.

    abstract::The desmoid tumors (DTs) are unusual soft-tissue tumors that have a propensity for aggressive local growth and may develop during, or soon after pregnancy. Pregnancy-associated DTs are uncommon and optimal management of this tumor has yet to be defined. Currently, controversy centers on the timing of surgical resectio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.98

    authors: Johner A,Tiwari P,Zetler P,Wiseman SM

    更新日期:2009-11-01 00:00:00

  • Optimal management of pulmonary metastases from colorectal cancer.

    abstract::The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical res...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.123

    authors: Limmer S,Unger L

    更新日期:2011-10-01 00:00:00

  • Minimally invasive cystectomy approaches in the treatment of bladder cancer.

    abstract::Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.52

    authors: Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

    更新日期:2012-06-01 00:00:00

  • Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.

    abstract::Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimiz...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.1.75

    authors: Yoon GH,Stein JP,Skinner DG

    更新日期:2005-02-01 00:00:00

  • Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era.

    abstract::Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.147

    authors: Ghavamian R,Hakimi AA

    更新日期:2009-12-01 00:00:00

  • Update on genetic predisposition to breast cancer.

    abstract::It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.38

    authors: Ahmed M,Lalloo F,Evans DG

    更新日期:2009-08-01 00:00:00

  • Treatment of childhood acute myeloid leukemia.

    abstract::Childhood acute myeloid leukemia is rare, but accounts for a significant number of malignancy-related deaths in this age group. However, the prognosis has improved over past decades, and survival rates of 60% and above have been reported. Still, this implies that more than a third of children and adolescents die from ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.5.917

    authors: ter Bals E,Kaspers GJ

    更新日期:2005-10-01 00:00:00

  • Specific challenges in the management of subungual melanoma.

    abstract::Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.216

    authors: De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

    更新日期:2011-05-01 00:00:00

  • The role of surgery in recurrent endometrial cancer.

    abstract:INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1190650

    authors: Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

    更新日期:2016-07-01 00:00:00

  • Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.

    abstract::Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.3.437

    authors: Kose MF,Meydanli MM,Tulunay G

    更新日期:2006-03-01 00:00:00

  • Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.5.785

    authors: Lekakis L,de Lima M

    更新日期:2008-05-01 00:00:00

  • Current radiotherapy techniques in NSCLC: challenges and potential solutions.

    abstract::Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1760094

    authors: Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

    更新日期:2020-05-01 00:00:00

  • Adrenocortical carcinoma: role of laparoscopic surgery in treatment.

    abstract::Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1295

    authors: Haleblian GE,Wilson C,Haddad D,Albala DM

    更新日期:2007-09-01 00:00:00

  • Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.

    abstract::More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.2.281

    authors: Amiel GE,Lerner SP

    更新日期:2006-02-01 00:00:00

  • Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.

    abstract:INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2018.1528146

    authors: Abdel-Rahman O,Oweira H,Giryes A

    更新日期:2018-12-01 00:00:00

  • Clinical management of borderline ovarian tumors.

    abstract::Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.90

    authors: Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

    更新日期:2010-07-01 00:00:00

  • miRNA expression profiles associated with diagnosis and prognosis in lung cancer.

    abstract::miRNAs, which are small single-stranded RNA molecules composed of 18-23 nts, act as oncogenes or tumor suppressor genes playing important roles in the processes of tumor formation, infiltration and metastasis. Lung cancer currently has the highest morbidity and mortality among all malignant tumors; yet, lack of early ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.870037

    authors: Jiang C,Hu X,Alattar M,Zhao H

    更新日期:2014-04-01 00:00:00

  • Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.

    abstract:INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1285702

    authors: Greenwell IB,Flowers CR,Blum KA,Cohen JB

    更新日期:2017-03-01 00:00:00

  • An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas.

    abstract:BACKGROUND:Published data concerning primary mediastinal sarcomas are limited to small-sized retrospective series.  This study reviewed the clinical outcomes of these cases from the SEER (surveillance, epidemiology and end results) database. METHODS:Primary mediastinal sarcomas (1988 - 2013) were assembled from the SE...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2017.1378576

    authors: Abdel-Rahman O

    更新日期:2017-11-01 00:00:00

  • Oncogenomics: prospects for the future.

    abstract::Genomics has generated a wealth of data that is now being used to identify additional molecular alterations associated with cancer development. Mapping these alterations in the cancer genome is a critical first step in dissecting oncological pathways. There are two ways in which cancer research has changed in recent y...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.891

    authors: Sakatani T,Onyango P

    更新日期:2003-12-01 00:00:00

  • Statistical approaches for evaluating body composition markers in clinical cancer research.

    abstract:INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1298446

    authors: Bayar MA,Antoun S,Lanoy E

    更新日期:2017-04-01 00:00:00

  • Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.

    abstract:INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal steroid hormones with relevant clinical consequences. Areas covered: After an extensive literature search, this narrative review addresses diagnostic manag...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1510325

    authors: Puglisi S,Perotti P,Cosentini D,Roca E,Basile V,Berruti A,Terzolo M

    更新日期:2018-11-01 00:00:00

  • Role of fludarabine in hematological malignancies.

    abstract::Fludarabine is a prodrug that is converted to the free nucleoside 9-beta-D-arabinosyl-2-fluoroadenine (F-ara-A), which enters cells and accumulates mainly as the 5'-triphosphate, F-ara-ATP. F-ara-ATP has multiple mechanisms of action, which are mostly directed toward DNA. Collectively, these actions affect DNA synthes...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.9.1141

    authors: Montillo M,Ricci F,Tedeschi A

    更新日期:2006-09-01 00:00:00

  • Temozolomide: a novel oral alkylating agent.

    abstract::Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combin...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.1.13

    authors: Danson SJ,Middleton MR

    更新日期:2001-06-01 00:00:00

  • Biomarkers for prostate cancer detection.

    abstract::Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.168

    authors: Reed AB,Parekh DJ

    更新日期:2010-01-01 00:00:00

  • Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma.

    abstract:INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1266261

    authors: Huang SB,Zheng CX

    更新日期:2017-01-01 00:00:00

  • Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

    abstract::Background: Patients with metastatic renal cell carcinoma (mRCC) are commonly treated with tyrosine kinase inhibitors (TKIs). An adverse effect frequently suffered by patients is lethargy, which often leads to dose reduction or drug cessation. We aimed to assess whether hypogonadism is related to treatment with TKIs. ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2019.1609355

    authors: Afshar M,Patel HRH,Jain A,Kumar A,Patel P,James ND,Porfiri E

    更新日期:2019-06-01 00:00:00

  • Pembrolizumab for the treatment of gastric cancer.

    abstract:INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1526084

    authors: Kamath SD,Kalyan A,Benson AB 3rd

    更新日期:2018-12-01 00:00:00

  • Optimal treatment of metastatic colorectal cancer.

    abstract::For over 40 years, fluorouracil has been the only drug registered for the treatment of metastatic colorectal cancer. During the past 5 years, combination chemotherapy regimens including either irinotecan or oxaliplatin have proven to be superior to fluorouracil monotherapy in randomized clinical trials, in terms of re...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.5.801

    authors: Pessino A,Sobrero A

    更新日期:2006-05-01 00:00:00